Professor Thozhukat Sathyapalan T.Sathyapalan@hull.ac.uk
Professor of Diabetes, Endocrinology and Metabolism
The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study
Sathyapalan, Thozhukat; Kilpatrick, Eric S.; Coady, Anne Marie; Atkin, Stephen L.
Authors
Eric S. Kilpatrick
Anne Marie Coady
Stephen L. Atkin
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is associated with increased risk of cardiovascular morbidity, whereas statins are proven to reduce cardiovascular mortality and morbidity through lipid-lowering and perhaps through their pleiotropic effects. Statins can also reduce testosterone in vitro by inhibiting ovarian theca-interstitial cell proliferation and steroidogenesis and reducing inflammation in vivo. OBJECTIVE: Our objective was to assess the effect of atorvastatin on inflammatory markers, insulin resistance, and biochemical hyperandrogenemia in patients with PCOS. DESIGN AND SETTING: We conducted a randomized, double-blind, placebo-controlled study at a tertiary care setting in United Kingdom. PATIENTS: Patients included 40 medication-naive patients with PCOS and biochemical hyperandrogenemia. METHODS: Patients were randomized to either atorvastatin 20 mg daily or placebo. MAIN OUTCOME MEASURES: The primary endpoint of the study was a change in the inflammatory marker high-sensitivity C-reactive protein. The secondary endpoints were a change in insulin resistance and total testosterone. Results: After 12 wk atorvastatin, there was a significant reduction (mean +/- sem) in total cholesterol (4.6 +/- 0.2 vs. 3.4 +/- 0.2 mmol/liter, P < 0.01), low-density lipoprotein cholesterol (2.9 +/- 0.2 vs. 1.8 +/- 0.2 mmol/liter, P < 0.01), triglycerides (1.34 +/- 0.08 vs. 1.08 +/- 0.13 mmol/liter, P <0.01), high-sensitivity C-reactive protein (4.9 +/- 1.4 vs. 3.4 +/- 1.1 mg/liter, P = 0.04), free androgen index (13.4 +/- 0.6 vs. 8.7 +/- 0.4, P < 0.01), testosterone (4.1 +/- 0.2 vs. 2.9 +/- 0.1 nmol/liter, P < 0.01) and insulin resistance as measured by homeostasis model assessment for insulin resistance (HOMA-IR) (3.3 +/- 0.4 vs. 2.7 +/- 0.4). There was a significant increase in SHBG (31.1 +/- 1.0 vs. 35.3 +/- 1.2 nmol/liter, P < 0.01). There was a positive correlation between the reduction in HOMA-IR in the atorvastatin group with the reduction in triglycerides and the reduction of free androgen index. There was a significant deterioration of HOMA-IR in the placebo group (3.0 +/- 0.4 vs. 3.8 +/- 0.5). CONCLUSIONS: This study suggests that atorvastatin is effective in reducing inflammation, biochemical hyperandrogenemia, and metabolic parameters in patients with PCOS after a 12-wk period
Citation
Sathyapalan, T., Kilpatrick, E. S., Coady, A. M., & Atkin, S. L. (2009). The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 94(1), 103-108. https://doi.org/10.1210/jc.2008-1750
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 10, 2008 |
Publication Date | Jan 1, 2009 |
Publicly Available Date | Mar 28, 2024 |
Journal | J.Clin.Endocrinol.Metab |
Print ISSN | 0021-972x |
Electronic ISSN | 1945-7197 |
Publisher | Oxford University Press |
Peer Reviewed | Peer Reviewed |
Volume | 94 |
Issue | 1 |
Pages | 103-108 |
DOI | https://doi.org/10.1210/jc.2008-1750 |
Keywords | Adult; Analysis; Blood; C-Reactive protein; Cell proliferation; Cholesterol; Heptanoic acids; Homeostasis |
Public URL | https://hull-repository.worktribe.com/output/423557 |
Publisher URL | https://academic.oup.com/jcem/article/94/1/103/2597834 |
You might also like
Association between Organochlorine Pesticides and Vitamin D in Female Subjects
(2023)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search